Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted ...

Another quarterly earnings announcement from Novo Nordisk and another downgrade to earnings guidance from the Danish ...

Revenue was down 5.9% from last year to $16.654, after increasing 10% the previous quarter. These results were better than ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and sales forecasts on Wednesday as growth slows ...

The first lawsuit, filed on Friday, claims Novo's bid breaches Pfizer's merger agreement and seeks to bypass antitrust review ...

Pfizer’s lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by ...

The new offer from Novo Nordisk constitutes a superior company proposal, Metsera says.

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Pfizer and Novo Nordisk continue to fight for ownership of obesity startup Metsera; CDER Director George Tidmarsh leaves his ...

Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera, but said ...